Table 2.
Univariate analysis for BCSS in MBC patients.
| Variables | Befor PSM | After PSM | |||||
|---|---|---|---|---|---|---|---|
| HRs | 95% CI | P | HRs | 95% CI | P | ||
| Age group | |||||||
| ≤ 60 years | 1 | [Reference] | 1 | [Reference] | |||
| > 60 years | 1.318 | 1.048-1.657 | 0.018 | 1.142 | 0.651-2.006 | 0.643 | |
| Race/ethnicity (n, %) | |||||||
| White | 1 | [Reference] | 1 | [Reference] | |||
| Black | 1.395 | 1.063-1.831 | 0.017 | 1.072 | 0.520-2.210 | 0.850 | |
| Other | 0.921 | 0.129-6.567 | 0.935 | – | – | ||
| Insurance (n, %) | |||||||
| No | 1 | [Reference] | 1 | [Reference] | |||
| Yes | 0.684 | 0.496-0.847 | 0.001 | 0.483 | 0.263-0.887 | 0.019 | |
| Grade (n, %) | |||||||
| Undifferentiated | 1 | [Reference] | 1 | [Reference] | |||
| Poorly differentiated | 0.774 | 0.433-1.382 | 0.387 | 1.427 | 0.196-10.361 | 0.725 | |
| Moderately differentiated | 0.386 | 0.190-0.784 | 0.008 | 0.674 | 0.061-7.436 | 0.748 | |
| Well differentiated | 0.284 | 0.107-0.758 | 0.012 | 0.876 | 0.055-14.013 | 0.925 | |
| Unknown | 0.692 | 0.358-1.341 | 0.276 | 0.616 | 0.039-9.851 | 0.732 | |
| Histology (n, %) | |||||||
| Metaplastic carcinoma | 1 | [Reference] | 1 | [Reference] | |||
| Adenosquamous carcinoma | 0.211 | 0.079-0.567 | 0.002 | 0.567 | 0.175-1.832 | 0.343 | |
| Carcinosarcoma | 1.637 | 1.079-2.484 | 0.021 | 2.440 | 0.964-6.177 | 0.060 | |
| Others | 0.765 | 0.341-1.718 | 0.517 | – | – | – | |
| Tumor size (n, %) | |||||||
| T1 | 1 | [Reference] | 1 | [Reference] | |||
| T2 | 2.273 | 1.519-3.401 | <0.001 | 1.375 | 0.560-3.372 | 0.487 | |
| T3 | 7.795 | 5.177-11.736 | <0.001 | 4.300 | 1.713-10.790 | 0.002 | |
| T4 | 13.221 | 8.591-20.346 | <0.001 | 17.252 | 6.688-44.503 | < 0.001 | |
| Unknown | 2.219 | 0.303-16.274 | 0.433 | 3.794 | 0.466-30.863 | 0.212 | |
| Lymph node state | |||||||
| N0 | 1 | [Reference] | 1 | [Reference] | |||
| N1 | 1.846 | 1.340-2.544 | <0.001 | 2.110 | 1.023-4.355 | 0.043 | |
| N2 | 1.993 | 1.204-3.299 | 0.007 | 3.978 | 1.506-10.507 | 0.005 | |
| N3 | 1.576 | 1.090-2.279 | 0.016 | 3.288 | 1.592-6.792 | 0.001 | |
| TNM stage (n, %) | |||||||
| I | 1 | [Reference] | 1 | [Reference] | |||
| II | 3.089 | 1.990-4.795 | <0.001 | 1.326 | 0.519-3.390 | 0.555 | |
| III | 10.396 | 6.600-16.376 | <0.001 | 6.260 | 2.447-16.015 | <0.001 | |
| IV | 34.276 | 20.439-57.479 | <0.001 | 23.360 | 8.138-67.058 | <0.001 | |
| Unknown | 1.616 | 0.218-11.969 | 0.638 | 4.069 | 0.489-33.840 | 0.194 | |
| ER status | |||||||
| negative | 1 | [Reference] | 1 | [Reference] | |||
| positive | 0.787 | 0.588-1.053 | 0.107 | 0.420 | 0.179-0.987 | 0.047 | |
| HER2 status | |||||||
| negative | 1 | [Reference] | 1 | [Reference] | |||
| positive | 0.784 | 0.487-1.262 | 0.316 | 0.584 | 0.327-1.044 | 0.069 | |
| PMRT | |||||||
| No | 1 | [Reference] | 1 | [Reference] | |||
| Yes | 0.727 | 0.579-0.913 | 0.006 | 0.370 | 0.196-0.697 | 0.002 | |
| PMCT | |||||||
| No | 1 | [Reference] | 1 | [Reference] | |||
| Yes | 0.904 | 0.718-1.139 | 0.393 | 0.754 | 0.376-1.511 | 0.426 | |
MBC, metaplastic breast cancer; PSM, propensity score-matching; ER, estrogen receptor; HER2, Human epidermal growth factor receptor 2; PMRT, post-mastectomy radiotherapy; PMCT, post-mastectomy chemotherapy; BCSS, Breast cancer-specific survival; HRs, Hazard ratios; CI, Confidence interval.